Exploratory, non-randomized, 3-group, microdosing clinical trial to investigate Gallium-68 (68Ga) labeled Platelet-Derived Growth Factor Beta (PDGFRß) targeting Positron Emission Tomography (PET) tracer (68Ga-ATH001) binding in the lungs in healthy participants versus participants with Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD)
Latest Information Update: 01 Apr 2026
At a glance
- Drugs [68Ga]Ga DOTA CYS ATH 001 (Primary)
- Indications Interstitial lung diseases; Systemic scleroderma
- Focus Adverse reactions
Most Recent Events
- 01 Apr 2026 New trial record